Delivery Order SPE2DB20D1004-SPE2DB22FE9J7

Award Date 12/1/21
Potential Completion Date 12/2/21
Potential Value $1.5K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $3,527.21 for the supply of Restasis 0.05% eye emulsion. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has no set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through November 2026. This IDC...
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $1,800.80 for the supply of Restasis 0.05% eye emulsion. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has no set-aside designation. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that serves as the primary vehicle for the company to provide a comprehensive range...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at $1,350.60, is for the delivery of RESTASIS 0.05% eye emulsion 30-count packages. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products...
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., was issued by the Defense Logistics Agency (DLA) for the delivery of Restasis 0.05% eye emulsion. The $2,851.11 firm fixed-price delivery order does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company to provide a comprehensive range of...
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $2,239.80 for the supply of Restasis 0.05% eye emulsion. The contract was awarded by the Defense Logistics Agency (DLA), a component of the Department of Defense, and has an ultimate completion date of June 6, 2023. The contract is a firm fixed-price type, and there is no set-aside designation. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract...
This federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, involves the delivery of Restasis 0.05% eye emulsion to the Defense Logistics Agency (DLA) Troop Support Medical. The $1,080.48 firm fixed-price delivery order is placed against an Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that AmerisourceBergen holds with the DLA. This IDC serves as a primary vehicle for the company to provide a comprehensive range of pharmaceutical...
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, is for the supply of Restasis 0.05% eye emulsion to various government agencies. The contract, valued at $11,768.61, is a delivery order under a larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical, worth up to $999,999,999.00 through December 31, 2025. This single-award IDC serves as the primary vehicle for Amerisourcebergen to deliver a...
This federal contract award is for the delivery of Restasis 0.05% eye emulsion from Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $1,320.58 delivery order was issued by the Defense Logistics Agency (DLA) and has a completion date of January 28, 2022. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical...
This federal contract award, valued at $3,020.16, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, which is a delivery order, is for the supply of Restasis 0.05% eye emulsion. This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC...
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order valued at $12,532.46 for the supply of RESTASIS 0.05% eye emulsion to the Defense Logistics Agency (DLA). The award falls under a larger Indefinite Delivery Contract (IDC) the company holds with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through December 2025. This IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of...
  • SPE2DB20D1004
    Indefinite Delivery Contract
  • SPE2DB20D1004-SPE2DB22FE9J7
    Delivery Order

This federal contract award to AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of Restasis 0.05% eye emulsion medication. The contract, valued at $1,527.64, was awarded by the Defense Logistics Agency (DLA), a component of the Department of Defense, and does not have a set-aside designation.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.

Generated 2/27/25, 10:05 AM